Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

FRESENIUS KABI PHARMA PORTUGAL LDA

NIF 504293753
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €7,294,053 119 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €7,294,053 119 contracts
A2 · Late Publication €8,764,579,416 6,658 contracts
Contract published to BASE more than 10 days after the signing date
LOW €8,764,579,416 6,658 contracts
A5 · Threshold Splitting €13,194,973 237 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €13,194,973 237 contracts
A6 · Low Competition €642,501 28 contracts
Only one bidder participated in a competitive procedure
MEDIUM €642,501 28 contracts
A9 · Price Overrun €10,356 2 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €10,356 2 contracts
A9 · Abnormal Price Reduction €10,913,762,149 3,635 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €10,913,762,149 3,635 contracts
C3 · Missing Mandatory Fields €2,574,530 174 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €2,574,530 174 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

105
€1,290,279,291
62
€538,926,641
451
€533,293,775
182
€505,558,203
79
€494,027,995
804
€445,880,145
751
€443,475,035
75
€425,762,035
44
€375,393,765
67
€367,680,536
221
€344,654,281
897
€344,402,811
104
€337,056,229
211
€337,054,236
291
€331,884,525
167
€288,618,109
44
€283,579,041
104
€279,750,321
83
€258,157,935
67
€238,778,479
Page 1 of 4 · 76 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 1 · 2 contracts

Medicamentos
PT · 6ba7573d86438b022ad3 · Ajuste Direto Regime G...
A9 · Price Overrun
€1,207 2025-06-26
MEDICAMENTOS
PT · 7828393 · Ajuste Direto Regime G...
A9 · Price Overrun A2 · Late Publication
€9,148 2021-08-25
Overview
Total Value Won
€11,055,352,507
Contracts Won
9,435
Score 321065 · CRITICAL RISK
NIF
504293753
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • A.C. [P-648f]
    Gerente
    since 2011-03-04
  • A.C. [P-648f]
    Gerente
    since 2012-03-08
  • A.C. [P-648f]
    Gerente
    since 2013-05-29
  • A.C. [P-648f]
    Gerente
    since 2014-03-21
  • A.C. [P-648f]
    Gerente
    since 2016-01-20
  • A.C. [P-648f]
    Gerente
    since 2018-10-15
  • A.C. [P-648f]
    Gerente
    since 2020-03-30
  • A.M. [P-a213]
    Gerente
    since 2020-09-08
  • A.M. [P-a213]
    Gerente
    since 2023-11-09
  • A.M. [P-a213]
    Gerente
    since 2024-11-28
  • A.C. [P-ad9a]
    Gerente
    since 2009-12-11
  • F.F. [P-1c40]
    Gerente
    since 2020-09-08
  • F.F. [P-1c40]
    Gerente
    since 2023-11-09
  • F.F. [P-1c40]
    Gerente
    since 2024-11-28
  • F.J. [P-c0b7]
    Gerente
    since 2011-03-04
  • F.J. [P-c0b7]
    Gerente
    since 2013-05-29
  • F.J. [P-c0b7]
    Gerente
    since 2014-03-21
  • G.L. [P-6763]
    Gerente
    since 2018-10-15
  • G.L. [P-6763]
    Gerente
    since 2020-03-30
  • G.L. [P-6763]
    Gerente
    since 2020-09-08
  • G.L. [P-6763]
    Gerente
    since 2023-11-09
  • G.L. [P-6763]
    Gerente
    since 2024-11-28
  • H.J. [P-df65]
    Gerente
    since 2012-03-08
  • H.J. [P-df65]
    Gerente
    since 2013-05-29
  • H.J. [P-df65]
    Gerente
    since 2014-03-21
  • J.M. [P-a6dd]
    Gerente
    since 2016-01-20
  • J.M. [P-a6dd]
    Gerente
    since 2018-10-15
  • J.M. [P-a6dd]
    Gerente
    since 2020-03-30
  • K.A. [P-e283]
    Gerente
    since 2020-03-30
  • M.C. [P-3c40]
    Gerente
    since 2020-03-30
  • M.P. [P-b919]
    Gerente
    since 2016-01-20
  • M.P. [P-b919]
    Gerente
    since 2018-10-15
  • M.P. [P-b919]
    Gerente
    since 2020-03-30
  • P.A. [P-4562]
    Gerente
    since 2024-11-28
  • F.K. [P-11e0]
    Sócio
    since 2013-12-20
  • F.K. [P-d255]
    Sócio
    since 2013-12-20
  • A.C. [P-648f]
    Gerente
    2020-09-08 → 2021-11-19
  • H.J. [P-df65]
    Gerente
    2016-01-20 → 2016-05-16
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned